Drug Profile
Oral human gammaglobulin
Alternative Names: IgPO; OralgamLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Sepulveda Ambulatory Care Center; University of California at Los Angeles
- Developer Protein Therapeutics; Research Corporation Technologies; University of California at Los Angeles
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease; Enterocolitis; Juvenile rheumatoid arthritis; Rheumatoid arthritis
Most Recent Events
- 29 Apr 2008 Oral gammaglobulin (Oralgam™) licensed to Latona Life Sciences worldwide for the treatment of Juvenile and adult rheumatoid arthritis and auto-immune induced hearing loss
- 24 Feb 2006 Phase-II clinical trials in Enterocolitis in USA (PO)
- 24 Feb 2006 PediaMed has completed enrolment in a phase II trial for Autistic enterocolitis in USA